SHORT MINI FUTURE - ELI LILLY & CO | Real-time Bid/Ask 07:44:05 01/07/2024 pm IST | ||
| 1.64 CHF / 1.65 CHF | +3.46% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 1.59 | -5.36% |
| 27/24/27 | 1.68 | +1.82% |
| 26/24/26 | 1.65 | +2.48% |
| 25/24/25 | 1.61 | -6.94% |
| 24/24/24 | 1.73 | -4.42% |
Delayed Quote Swiss Exchange
Last update June 28, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| MLLAIV | |
| ISIN | CH1349613237 |
| Date issued | 19/06/2024 |
| Strike | 1,088 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 1.82 CHF |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.81 CHF |
|---|---|
| Lowest since issue | 1.59 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.62% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- MLLAIV Certificat
